1151 PHARMACEUTICAL DOSAGE FORMS
that observed or anticipated for an immediate-release dosage form. Expressions such as “prolonged-release”, “repeat-action”, “controlled-release”, “long-acting”, and “sustained-release” also have been used to describe such dosage forms. However, the term “extended-release” is used for official article titles.
Download 1151 PHARMACEUTICAL DOSAGE FORMS
Information
Domain:
Source:
Link to this page:
Documents from same domain
USP <51> Antimicrobial Effectiveness Testing
latam-edu.usp.orgIf the diluted product exhibits antimicrobial properties, specific neutralizers may need to be incorporated into the diluents or the recovery media. The ability of the procedure to measure preservative efficacy may be compromised if the method suitability requires significant dilution (10 −2 or 10 −3) as this will affect the measured recovery
1664 〉〉〉〉 ASSESSMENT OF DRUG PRODUCT …
latam-edu.usp.orgadministration ports, overwraps, adminstration accessories, labels, cardboard boxes, and shrink wrap. A Primary Packaging Component is in direct contact or may come into direct contact with the product (e.g., IV bag). A Secondary Packaging Component is in direct contact with a primary packaging component and may provide additional protection
659 PACKAGING AND STORAGE REQUIREMENTS
latam-edu.usp.orgAncillary component:A component or entity that may come into contact with a Tertiary packaging component during the distribution, storage, and/or transportation of the packaged article (e.g., pallets, skids, and shrink wrap).
Module 08 USP 1115 Bioburden Control of Non-Sterile …
latam-edu.usp.orgUnlike aseptic processing for which facility requirements are generally uniform in specification and performance, nonsterile product manufacturing environments typically involve diverse products and microbial contamination control requirements. In general, liquid, cream, or ointment products require a greater level of
USP <71> Sterility Tests - United States Pharmacopeia
latam-edu.usp.orgThe view from USP <1211> Sterilization and Sterility Assurance of Compendial Articles : 6 ... For products containing a mercurial preservative that cannot be tested by the ... Used for sterility testing of viscous products and for devices having tubes with small lumen.
1117 MICROBIOLOGICAL BEST LABORATORY PRACTICES
latam-edu.usp.orgWhenever possible, sampling equipment should be loaded with its microbiological recovery media in the environment that is to be sampled. All testing in laboratories used for critical testing procedures, such as sterility testing of final dosage forms, bulk product, seed
71 〉〉〉〉 STERILITY TESTS
latam-edu.usp.orgof the test. Modify the conditions in order to eliminate the antimicrobial activity, and repeat the Method Suitability Test. This method suitability is performed (a) when the test for sterility has to be carried out on a new product; and (b) whenever there is a change in the experimental conditions of the test.
1092 THE DISSOLUTION PROCEDURE: DEVELOPMENT AND …
latam-edu.usp.org5.4 Precision 5.4.1 Repeatability of Analysis 5.4.2 Intermediate Precision/Ruggedness 5.4.3 Reproducibility 5.5 Robustness 5.6 Stability of Standard and Sample Solutions ... (such as dynamic solubility, potentiometric titration, or turbidity measurement methods). (USP …
STERILIZATION OF COMPENDIAL ARTICLES
latam-edu.usp.orgFor steam and dry heat, the D-value is a function of temperature. In gas sterilization (ethylene oxide, ClO , or O ), D-values are a function of the chemical concentration, relative humidity, and temperature. Similarly, for liquid chemical sterilization the D-value is a function of the temperature and sterilant concentration.
660 〉〉 CONTAINERS—GLASS
latam-edu.usp.orgglass containers will raise the hydrolytic resistance from a moderate to a high level, changing the classification of the glass to Type II. The following recommendations can be made as to the suitability of the glass type for containers for pharmaceutical products, based on the tests for hydrolytic resistance.
Related documents
2.9.3. DISSOLUTION TEST FOR SOLID DOSAGE FORMS
www.uspbpep.com2.9.3. Dissolution test for solid dosage forms EUROPEAN PHARMACOPOEIA 6.0 beaker with a capacity of at least 4 litres filled with water maintained at 36-37 °C, unless otherwise prescribed. The apparatuses may also be placed together in a vessel with a capacity of …
Dosage Form Design: Pharmaceutical and Formulation ...
downloads.lww.comingredients or excipients, produces dosage forms of various types. The pharmaceutical ingredients solubilize, suspend, thicken, dilute, emulsify, sta-bilize, preserve, color, fl avor, and fashion medici-nal agents into effi cacious and appealing dosage forms. Each type of dosage form is unique in its physical and pharmaceutical characteristics.
Guideline on the pharmacokinetic and clinical evaluation ...
www.ema.europa.euProlonged release dosage forms are modified release dosage forms showing a sustained release compared to that of an immediate release dosage form administered by the same route. • Delayed release dosage form: The release of the active substance from such modified release dosage forms is delayed for a certain period after administration or ...
Pharmaceutical Dosage Forms - Temple University
pharmacy.temple.edumodified-release solid oral dosage forms encompass delayed/enteric-coated and extended-release drug products. Besides the delayed- and/or extended-release features, other newer types of oral modified-release products may include pulsatile …
PROPOSAL TO WAIVE IN VIVO BIOEQUIVALENCE …
www.who.intimmediate release, solid oral dosage forms Deadline Consolidation of first list for consideration of biowaiver October 2004 Consolidation of comments March 2005 Discussion during consultation July 2005 Additional studies and review August-September 2005 Mailing of revised version for comments September 2005
ICH HARMONISED TRIPARTITE GUIDELINE
database.ich.organd release for public consultation. 19 May 2011 Current Step 4 version Code History Date Q11 ... substance can affect the choice of dosage form). The Quality Target Product Profile (QTPP), potential CQAs of the drug product (as defined in ICH Q8) and previous ...
HIGHLIGHTS OF PRESCRIBING INFORMATION • In linezolid-or ...
pi.lilly.com-----DOSAGE FORMS AND STRENGTHS-----Delayed-release capsules: 20 mg, 30 mg, and 60 mg (3)-----CONTRAINDICATIONS-----• Concomitant use of an MAOI antidepressant with CYMBALTA is contraindicated • Use of CYMBALTA within 14 days of stopping an MAOI antidepressant is contraindicated ...